Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03781986 · ClinicalTrials.gov registry record · Phase 1

APG-115 in Salivary Gland Cancer Trial

A Phase 1 study of Salivary Gland Cancer and Malignant Salivary Gland Cancer, sponsored by University of Michigan Rogel Cancer Center.

Active
Registry status
Phase 1
Development phase
41
Enrollment target
3
Study locations

NCT03781986 is a Phase 1 study of Salivary Gland Cancer and Malignant Salivary Gland Cancer that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 41 participants, below the 60-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (32% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03781986, a Phase 1 study of Salivary Gland Cancer and Malignant Salivary Gland Cancer, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
41 participants
Enrollment target
3
Study locations

Study Summary

This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 monotherapy).

Conditions Studied

Salivary Gland Cancer Malignant Salivary Gland Cancer

Interventions

  • DRUG Carboplatin
  • DRUG APG-115

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • University of Chicago - Chicago

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2019-10-28
Est. Completion 2027-01
Phase Phase 1

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03781986

The ClinicalTrials.gov registry entry for NCT03781986 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (32% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Salivary Gland Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.

NCT03781986 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT03781986 about?

NCT03781986 is a clinical study titled "APG-115 in Salivary Gland Cancer Trial". This is a phase I/II trial to evaluate the efficacy of APG-115 +/- Carboplatin for the treatment p53 wild-type malignant salivary gland cancer. Part 1 consisted of 2 arms, arm A (APG-115 monotherapy) and arm B (APG-115 + Carboplatin) and was terminated early. Part 2 is a single arm study (APG-115 ...

What is the current status of trial NCT03781986?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-10-28. Estimated completion is 2027-01.

What conditions does trial NCT03781986 study?

This clinical trial studies the following conditions: Salivary Gland Cancer, Malignant Salivary Gland Cancer.

What interventions are being tested in trial NCT03781986?

The interventions under investigation include: Carboplatin (DRUG), APG-115 (DRUG).

Who is sponsoring clinical trial NCT03781986?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03781986 being conducted?

This trial has 3 study locations across Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Salivary Gland Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Salivary Gland Cancer

All registered trials for this condition

Malignant Salivary Gland Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.